LivaNova PLC LIVN
LivaNova PLC is a market-leading global medical technology company. The Company designs, develops, manufactures, markets, and sells products, therapies, and services that are consistent with LivaNova's mission to "create ingenious medical solutions that ignite patient turnarounds." LivaNova is a public limited company organized under the laws of England and Wales and is headquartered in London, England. LivaNova's ordinary shares are listed for trading on the Nasdaq under the symbol "LIVN."
LivaNova identifies operating segments based on how it manages, evaluates, and internally reports its business activities to allocate resources, develop and execute its strategy, and assess performance. LivaNova has two reportable segments: Cardiopulmonary and Neuromodulation. "Other" includes non-allocated corporate expenses and the non-cannula results of the Company's former ACS segment, which was wound down during 2024.
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.39B | $1.25B | $1.15B | $1.02B | $1.04B | $934.2M | $1.08B | $1.11B | $1.01B | $964.9M |
| Cost of revenue | $448.2M | $400.0M | $397.7M | $314.6M | $329.4M | $339.5M | $360.4M | $361.3M | $353.2M | $367.8M |
| Gross profit | $939.9M | $853.5M | $755.8M | $707.2M | $706.0M | $594.8M | $723.8M | $745.6M | $651.6M | $559.5M |
| R&D | $185.8M | $182.5M | $193.8M | $155.8M | $183.4M | $152.9M | $146.8M | $145.9M | $109.5M | $82.1M |
| SG&A | $548.8M | $508.9M | $502.7M | $469.2M | $471.9M | $446.6M | $528.5M | $465.0M | $380.1M | $355.2M |
| Total operating expenses | — | — | — | — | — | — | — | — | $556.0M | $528.1M |
| Operating income | $199.4M | $129.1M | -$68.5M | -$76.8M | -$784.0K | -$273.9M | -$171.6M | -$248.1M | $96.5M | $33.4M |
| Interest expense | $49.3M | $63.1M | $58.9M | $48.2M | $50.2M | $40.8M | $15.1M | $9.8M | $7.8M | $10.6M |
| Pre-tax income | -$220.8M | $88.3M | -$81.2M | -$75.1M | -$124.5M | -$348.0M | -$188.4M | -$247.4M | $121.1M | $25.7M |
| Income tax | $21.6M | $25.1M | $98.9M | $11.1M | $11.2M | $960.0K | $30.4M | $69.6M | $50.0M | $5.1M |
| Net income | -$242.5M | $63.2M | $17.6M | -$86.2M | -$135.8M | -$348.8M | -$157.6M | -$189.4M | -$25.1M | -$62.8M |
| EPS, basic | -4.45 | 1.17 | 0.33 | -1.61 | -2.68 | -7.18 | -3.21 | -3.91 | -0.52 | -1.29 |
| EPS, diluted | -4.45 | 1.16 | 0.32 | -1.61 | -2.68 | -7.18 | -3.26 | -3.91 | -0.52 | -1.28 |
| Shares, diluted (wtd. avg.) | 54.5M | 54.6M | 54.2M | 53.5M | 50.6M | 48.6M | 48.3M | 48.5M | 48.5M | 49.0M |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $635.6M | $428.9M | $266.5M | $515.6M | $208.0M | $252.8M | $61.1M | $47.2M | $93.6M | $39.8M |
| Receivables | $216.0M | $193.2M | $215.1M | $183.1M | $185.4M | $184.4M | $257.8M | $256.1M | $282.1M | $213.3M |
| Inventory | $164.7M | $147.6M | $147.9M | $129.4M | $105.8M | $115.3M | $164.2M | $153.5M | $144.5M | $133.0M |
| Total current assets | $1.10B | $1.13B | $988.2M | $886.1M | $679.2M | $708.0M | $549.4M | $533.3M | $869.9M | $812.7M |
| Property, plant and equipment | $242.6M | $170.3M | $154.2M | $147.2M | $150.1M | $163.8M | $181.4M | $191.4M | $192.4M | $203.7M |
| Goodwill | $792.8M | $750.0M | $782.9M | $768.8M | $899.5M | $922.3M | $915.8M | $956.8M | $784.2M | $691.7M |
| Other intangibles | $230.0M | $237.3M | $261.2M | $368.6M | $399.7M | $437.6M | $607.5M | $770.4M | $446.4M | $609.2M |
| Total assets | $2.61B | $2.51B | $2.43B | $2.29B | $2.20B | $2.40B | $2.41B | $2.55B | $2.50B | $2.34B |
| Accounts payable | $97.2M | $69.7M | $80.8M | $74.3M | $68.0M | $73.7M | $85.9M | $76.7M | $85.9M | $71.9M |
| Short-term debt | $30.9M | $77.3M | $17.5M | $20.9M | $226.9M | $8.4M | $73.2M | $23.3M | $25.8M | $21.3M |
| Total current liabilities | $808.1M | $392.1M | $335.0M | $297.4M | $697.0M | $309.1M | $512.6M | $496.7M | $406.0M | $349.9M |
| Long-term debt | $345.2M | $549.6M | $568.5M | $518.1M | $9.8M | $642.3M | $260.3M | $139.5M | $62.0M | $75.2M |
| Total liabilities | $1.41B | $1.19B | $1.15B | $1.09B | $906.3M | $1.29B | $1.03B | $1.05B | $688.6M | $635.7M |
| Retained earnings | -$1.15B | -$903.2M | -$966.5M | -$984.0M | -$897.8M | -$762.0M | -$406.8M | -$251.6M | -$39.7M | -$14.6M |
| Total equity | $1.20B | $1.32B | $1.28B | $1.21B | $1.29B | $1.11B | $1.38B | $1.50B | $1.82B | $1.71B |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $254.3M | $183.0M | $74.9M | $69.9M | $102.5M | -$79.4M | -$91.1M | $120.5M | $91.3M | $90.2M |
| Depreciation and amortisation | $28.6M | $25.1M | $24.7M | $22.4M | $24.5M | $29.0M | $30.3M | $32.7M | $37.1M | $39.9M |
| Stock-based compensation | $36.3M | $33.9M | $36.4M | $44.8M | $40.6M | $35.1M | $32.6M | $26.9M | $19.1M | $19.6M |
| Capital expenditure | $81.0M | $47.1M | $35.0M | $26.5M | $25.5M | $35.0M | $24.7M | $37.2M | $32.9M | $38.4M |
| Investing cash flow | -$72.9M | -$48.2M | -$40.3M | -$38.4M | $36.9M | -$41.8M | -$41.3M | -$120.6M | -$52.9M | -$44.5M |
| Financing cash flow | -$285.7M | $18.6M | $21.5M | $280.1M | -$181.5M | $310.8M | $146.6M | -$42.3M | $11.3M | -$118.0M |
| Buybacks | — | — | — | — | — | $0 | $0 | $50.0M | $0 | $54.5M |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001104659-26-050937.
Plot the figures US dollars
- Revenue
- Gross profit
- Net income
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $964.9M | $1.01B | $1.11B | $1.08B | $934.2M | $1.04B | $1.02B | $1.15B | $1.25B | $1.39B |
| Gross profit | $559.5M | $651.6M | $745.6M | $723.8M | $594.8M | $706.0M | $707.2M | $755.8M | $853.5M | $939.9M |
| Net income | -$62.8M | -$25.1M | -$189.4M | -$157.6M | -$348.8M | -$135.8M | -$86.2M | $17.6M | $63.2M | -$242.5M |
Recent filings and events
- Results announced The quarterly or annual earnings release. Arrives four times a year from almost every company here. Item 2.02
- Shareholder vote The results of the annual meeting or a special vote. Item 5.07
- Results announced Item 2.02
- Annual report filed A new 10-K. The figures and the business description on this site come from it. Form 10-K
- Results announced Item 2.02
- Officer or director change Someone at the top arrived or left. The item covers everything from a board retirement to a chief executive being removed, and only the filing itself says which. Item 5.02
- Results announced Item 2.02
- Officer or director change Item 5.02
- Results announced Item 2.02
- Officer or director change Item 5.02
- Shareholder vote Item 5.07
- Regulation FD disclosure Something the company told the market and had to tell everyone at once - usually a slide deck or a press release. Item 7.01
Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.
Others in SIC 3845
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| MDT | Medtronic plc | $122.04B | 25.6x | 8.4% |
| ITGR | Integer Holdings Corp | $4.30B | 43.8x | 8.0% |
| TMDX | TransMedics Group, Inc. | $2.45B | 14.5x | 37.1% |
| AXGN | Axogen, Inc. | $2.05B | — | 20.2% |
| BLFS | BIOLIFE SOLUTIONS INC | $1.89B | — | 28.9% |
| CNMD | CONMED Corp | $1.48B | 32.6x | 5.2% |
| CBLL | Ceribell, Inc. | $1.04B | — | 36.1% |
| CV | CapsoVision, Inc | $349.8M | — | 15.3% |